Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor epidermal growth factor receptor (EGFR) mutations Meeting Abstract

  

Authors:	Janjigian, Y. Y.; Park, B. J.; Kris, M. G.; Miller, V. A.; Riely, G. J.; Zheng, J.; Dycoco, J. P.; Shen, R.; Azzoli, C. G.
Abstract Title:	Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor epidermal growth factor receptor (EGFR) mutations
Meeting Title:	45th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	27
Issue:	15 Suppl.
Meeting Dates:	2009 May 29-Jun 2
Meeting Location:	Orlando, FL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2009-05-20
Start Page:	387s
Language:	English
ACCESSION:	WOS:000276606605124
PROVIDER:	wos
Notes:	Meeting Abstract: 7523 -- Source: Wos